SABS (STOCKS)
SAB Biotherapeutics, Inc. Common Stock
$3.870000
+0.540000 (+16.22%)
Prev close: $3.330000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Samuel J. Reich
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $298.21M
- Employees
- 63
- P/E (TTM)
- -1.58
- P/B (TTM)
- 1.11
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.35 | $-0.23 | -0.1171 | -50.28% |
|
Dec 2025 (Q4)
|
$-0.35 | $-0.20 | -0.1473 | -72.67% |
|
Sep 2025 (Q3)
|
$-0.15 | $-0.52 | +0.3661 | +70.94% |
|
Jun 2025 (Q2)
|
$-1.09 | $-0.81 | -0.2781 | -34.25% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $57.78M |
| Operating Expenses | $58.18M |
| Research and Development | $40.09M |
| Other Operating Expenses | $18.09M |
| Operating Income/Loss | -$58.18M |
| Income/Loss From Continuing Operations After Tax | -$398.43K |
| Income/Loss From Continuing Operations Before Tax | -$398.43K |
| Net Income/Loss | -$398.43K |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$398.43K |
| Net Income/Loss Available To Common Stockholders, Basic | -$26.49M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $52.18M |
| Preferred Stock Dividends And Other Adjustments | $26.09M |
| Basic Earnings Per Share | -$1.45 |
| Diluted Earnings Per Share | -$2.11 |
| Basic Average Shares | 83,074,875 |
| Diluted Average Shares | 171,753,674 |
| Assets | $248.47M |
| Current Assets | $112.78M |
| Noncurrent Assets | $135.69M |
| Fixed Assets | $13.81M |
| Other Non-current Assets | $121.87M |
| Liabilities | $21.22M |
| Current Liabilities | $9.85M |
| Accounts Payable | $3.54M |
| Wages | $2.89M |
| Other Current Liabilities | $3.41M |
| Noncurrent Liabilities | $11.37M |
| Equity | $227.25M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $227.25M |
| Liabilities And Equity | $248.47M |
| Net Cash Flow From Operating Activities | -$51.25M |
| Net Cash Flow From Operating Activities, Continuing | -$51.25M |
| Net Cash Flow From Investing Activities | -$192.02M |
| Net Cash Flow From Investing Activities, Continuing | -$192.02M |
| Net Cash Flow From Financing Activities | $258.39M |
| Net Cash Flow From Financing Activities, Continuing | $258.39M |
| Net Cash Flow | $15.12M |
| Net Cash Flow, Continuing | $15.12M |
| Comprehensive Income/Loss | -$605.39K |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$509.60K |
| Other Comprehensive Income/Loss | $9.51M |